D Rischin

Summary

Affiliation: University of Melbourne
Country: Australia

Publications

  1. ncbi A phase I trial of docetaxel and gemcitabine in patients with advanced cancer
    D Rischin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Ann Oncol 11:421-6. 2000
  2. ncbi Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics
    D Rischin
    Division of Haematology and Medical Oncology and Statistical Centre, Peter MacCallum Cancer Institute, Melbourne, Austtralia
    Ann Oncol 13:1810-8. 2002
  3. ncbi A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis
    D Rischin
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Vic
    Med J Aust 173:125-7. 2000
  4. ncbi Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation
    Danny Rischin
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    J Clin Oncol 20:1845-52. 2002
  5. ncbi Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study
    H M Prince
    Blood and Marrow Transplant Service, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Ann Oncol 10:479-81. 1999
  6. ncbi CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy
    H M Prince
    Blood and Marrow Transplant Service, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Cytotherapy 4:147-55. 2002
  7. ncbi Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer
    M J Millward
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    J Clin Oncol 15:750-8. 1997
  8. ncbi A phase II trial of paclitaxel and epirubicin in advanced breast cancer
    D Rischin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Br J Cancer 83:438-42. 2000
  9. ncbi Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer
    D Rischin
    Division of Hematology and Medical Oncology, and Statistical Centre, Peter MacCallum Cancer Institute, Melbourne, Australia
    J Clin Oncol 19:535-42. 2001
  10. ncbi Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
    J Zalcberg
    Department of Medical Oncology, Austin and Repatriation Medical Centre, Melbourne, Australia
    J Clin Oncol 16:1948-53. 1998

Detail Information

Publications74

  1. ncbi A phase I trial of docetaxel and gemcitabine in patients with advanced cancer
    D Rischin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Ann Oncol 11:421-6. 2000
    ..Docetaxel and gemcitabine are active in a broad range of malignancies. The objective of this phase I trial was to determine the maximally tolerated doses of the combination of docetaxel and gemcitabine...
  2. ncbi Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics
    D Rischin
    Division of Haematology and Medical Oncology and Statistical Centre, Peter MacCallum Cancer Institute, Melbourne, Austtralia
    Ann Oncol 13:1810-8. 2002
    ..The objective of this phase I trial was to determine the maximally tolerated doses of the combination of docetaxel, epirubicin and cyclophosphamide...
  3. ncbi A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis
    D Rischin
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Vic
    Med J Aust 173:125-7. 2000
    ..To determine patient preferences and cost differences between home-based and hospital-based chemotherapy...
  4. ncbi Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation
    Danny Rischin
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    J Clin Oncol 20:1845-52. 2002
    ..To determine the efficacy and safety of epirubicin, cisplatin, and infusional fluorouracil (5-FU) chemotherapy followed by radiation with concurrent cisplatin in patients with locally and/or regionally advanced nasopharyngeal cancer...
  5. ncbi Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study
    H M Prince
    Blood and Marrow Transplant Service, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Ann Oncol 10:479-81. 1999
    ..This phase I study was designed to determine the optimal dosages of a novel repetitive high-dose therapy regimen for patients with metastatic breast cancer (MBC)...
  6. ncbi CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy
    H M Prince
    Blood and Marrow Transplant Service, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Cytotherapy 4:147-55. 2002
    ..8 x 10(6)/kg), CliniMACS-selected CD34+ cells (in the doses utilized in this study of < or = 2.6 x 10(6)/kg) result in significantly prolonged recovery...
  7. ncbi Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer
    M J Millward
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    J Clin Oncol 15:750-8. 1997
    ....
  8. ncbi A phase II trial of paclitaxel and epirubicin in advanced breast cancer
    D Rischin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Br J Cancer 83:438-42. 2000
    ..Grade 3 or 4 non-haematologic toxicity was uncommon. In conclusion, paclitaxel 175 mg m(-2) and epirubicin 75 mg m(-2) is a well tolerated, promising regimen for the treatment of advanced breast cancer...
  9. ncbi Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer
    D Rischin
    Division of Hematology and Medical Oncology, and Statistical Centre, Peter MacCallum Cancer Institute, Melbourne, Australia
    J Clin Oncol 19:535-42. 2001
    ..To determine the maximum-tolerated dose of tirapazamine when combined with cisplatin and radiation in patients with T3/4 and/or N2/3 squamous cell carcinoma of the head and neck...
  10. ncbi Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
    J Zalcberg
    Department of Medical Oncology, Austin and Repatriation Medical Centre, Melbourne, Australia
    J Clin Oncol 16:1948-53. 1998
    ..A recently reported phase I study of the combination of docetaxel and cisplatin recommended a dose of 75 mg/m2 of both drugs every 3 weeks for subsequent phase II study...
  11. ncbi Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer
    B Solomon
    Peter MacCallum Cancer Institute, St. Andrews Place, East Melbourne, Vic. 3002, Australia
    Lung Cancer 41:353-61. 2003
    ..Paclitaxel can be safely given twice-weekly at a dose of 30 mg/m(2) in combination with weekly cisplatin (20 mg/m(2)) and thoracic RT (60 Gy), and this regimen has significant activity in stage III NSCLC...
  12. ncbi Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study
    H M Prince
    Blood and Marrow Transplant Service, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria 3000, Australia
    Gynecol Oncol 81:216-24. 2001
    ..5 mg/m(2)/day for 5 days. This outpatient HDT regimen combines three of the most active drugs in ovarian cancer with acceptable toxicity and promising activity...
  13. ncbi F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment
    M P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, A Beckett Street, Melbourne, Victoria 3000, Australia
    Cancer 92:886-95. 2001
    ..The authors investigated FDG-PET staging in radical RT candidates with unresectable NSCLC...
  14. ncbi Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial
    S Loi
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, A Beckett Street, Melbourne, Victoria 8006, Australia
    Br J Cancer 92:655-61. 2005
    ..For future trials, oxaliplatin 85 mg m(-2) and 5-FU 200 mg m(-2) day(-1) continuous infusion 96 h week(-1) is the recommended dose when combined with 50.4 Gy of pelvic radiotherapy...
  15. ncbi A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer
    D Rischin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Invest New Drugs 17:73-80. 1999
    ..In conclusion, paclitaxel 175 mg/m2 and epirubicin 75 mg/m2 is recommended for phase II and III studies...
  16. ncbi Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: a case report and review of the literature
    B Ma
    Division of Medical Oncology, Petcr MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Ann Oncol 12:1015-7. 2001
    ..The limited relevant literature is presented. We conclude that chemotherapy should be used with extreme caution in Bloom's syndrome patients...
  17. ncbi Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group
    S Y Ngan
    Peter MacCallum Cancer Institute, Victoria, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 50:883-7. 2001
    ..To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum...
  18. ncbi Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature
    L Mileshkin
    Blood and Marrow Transplant Service, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Bone Marrow Transplant 27:559-63. 2001
    ..The available relevant literature is reviewed...
  19. ncbi Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer
    F L Day
    Department of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Melbourne, Victoria 8006, Australia
    Br J Cancer 104:265-71. 2011
    ..The aim of this phase I trial was to assess the maximum tolerated dose (MTD) of a novel weekly docetaxel and cisplatin regimen concurrent with radical radiotherapy...
  20. ncbi Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide
    L K Webster
    Division of Research, Peter MacCallum Cancer Institute, Melbourne, Vic, Australia
    Cancer Chemother Pharmacol 39:557-60. 1997
    ..06 microliter/ml) in any patient. Plasma polysorbate 80 levels following an intravenous infusion of 120 mg/m2 etoposide or of docetaxel at doses used in Phase II trials, are insufficient to show modulation of MDR in vitro...
  21. ncbi Phase I trial of cremophor EL with bolus doxorubicin
    M J Millward
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Clin Cancer Res 4:2321-9. 1998
    ..The pharmacokinetic interaction between cremophor and doxorubicin is quantitatively similar to that described in trials of paclitaxel with doxorubicin and suggests that the cremophor in the paclitaxel formulation is responsible...
  22. ncbi Association of acquired Pelger-Huet anomaly with taxoid therapy
    S K Juneja
    Department of Pathology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Br J Haematol 93:139-41. 1996
    ..001) and for paclitaxel compared with controls (P = 0.007). We conclude that taxoid therapy produces transient APHA which peaks between days 3 and 9 and is more pronounced with docetaxel than with paclitaxel...
  23. ncbi A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients
    S G Poole
    Department of Pharmacy, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    Ann Oncol 13:949-55. 2002
    ....
  24. ncbi Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel
    R Jennens
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Gynecol Oncol 91:190-3. 2003
    ..4, 2.0). CONCLUSIONS: Increasing the duration of paclitaxel infusions from 3 to 6 h does not result in a statistically significant increase in the degree of neutropenia. Any additional neutropenia is likely to be of brief duration...
  25. ncbi Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01
    A V Tinker
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Gynecol Oncol 104:647-53. 2007
    ..To determine the response rate of weekly docetaxel in women with relapsed epithelial ovarian cancer previously treated with paclitaxel and at least one line of platinum-based chemotherapy...
  26. ncbi Clinical verification of the superiority of the current International Union Against Cancer staging criteria in an Australian population of patients with nasopharyngeal carcinoma
    J Corry
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Australas Radiol 48:509-15. 2004
    ..96; OS: P = 0.96). This study confirms the prognostic superiority of the fifth edition UICC staging system over the fourth edition staging system in an Australian NPC population...
  27. ncbi Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy
    H M Prince
    Blood and Marrow Transplant Service, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Cytotherapy 4:137-45. 2002
    ..However, we were unable to acquire sufficient CD34+ cells to perform this processing in 45% (13/29) of patients and further improvements in yield are required to overcome the modest delay in neutrophil and platelet recovery...
  28. ncbi Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation
    J Corry
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    J Med Imaging Radiat Oncol 52:503-10. 2008
    ..The duration of use of PEG tubes was significantly longer, a median 139 days compared with a median 66 days for NGT. We found no evidence to support the routine use of PEG tubes over NGT in this patient group...
  29. ncbi Radiation recall reaction following gemcitabine
    G Fogarty
    Division of Radiation Oncology, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne Vic, Australia
    Lung Cancer 33:299-302. 2001
    ..Cessation of the precipitating drug is the most important step in management and systemic steroids may hasten symptomatic relief...
  30. ncbi Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line
    X F Hu
    Trescowthick Laboratory, Peter MacCallum Cancer Institute, Melbourne, Australia
    Br J Cancer 79:831-7. 1999
    ..This study demonstrates that MDR1 expression can be induced by analogues of anthracyclines not pumped by Pgp, and that this induction appears to be stable despite a 3-week drug-free period...
  31. ncbi Subxiphoid partial pericardiectomy with or without sclerosant instillation in the treatment of symptomatic pericardial effusions in patients with malignancy
    A Chan
    Department of Medical Oncology, Austin Hospital, Melbourne, Australia
    Cancer 68:1021-5. 1991
    ..The survival range was 0.1 to 18 months (median, 5 months). Subxiphoid partial pericardiectomy with or without intrapericardial sclerosant is a safe and efficacious treatment for malignant pericardial effusions...
  32. ncbi Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate
    M J Dooley
    Pharmacy, Peter MacCallum Cancer Institute, St Andrew s Place, East Melbourne, 3002, Australia
    Eur J Cancer 38:44-51. 2002
    ..D.) 17%) and -14% (S.D. 16%), respectively. Further prospective evaluation of the Chatelut formula is required before it can be recommended for routine clinical application...
  33. ncbi N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders-results of Trans Tasman Radiation Oncology Group Study 98.02
    June Corry
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Head Neck 30:737-42. 2008
    ....
  34. ncbi Promising results of a cooperative group phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801)
    Samuel Y K Ngan
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Dis Colon Rectum 48:1389-96. 2005
    ..5 years of follow-up...
  35. ncbi Results of treatment intensification for progressive locoregional disease in head-and-neck cancer patients undergoing postoperative radiotherapy
    June Corry
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 61:1416-22. 2005
    ..We present our experience using treatment intensification for such patients...
  36. ncbi Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer
    Sandro V Porceddu
    Division of Radiation Oncology, St Andrews Place, East Melbourne, Australia
    Head Neck 27:175-81. 2005
    ....
  37. ncbi Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02)
    Danny Rischin
    Division of Haematology and Medical Oncology, University of Melbourne, Peter MacCallum Cancer Centre, Locked Bag No 1, A Beckett St, Melbourne 8006, Australia
    J Clin Oncol 23:79-87. 2005
    ..To select one of two chemoradiotherapy regimens for locally advanced squamous cell carcinoma (SCC) of the head and neck as the experimental arm for the next Trans-Tasman Radiation Oncology Group phase III trial...
  38. ncbi PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy
    Kenneth B Roberts
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA
    Lung Cancer 47:49-57. 2005
    ..PET may be valuable after pneumonectomy if the patient is being considered for adjuvant or salvage radiotherapy although specificity may be reduced due to post-operative inflammatory changes...
  39. ncbi The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin
    Clare L Scott
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, East Melbourne, Victoria, 8006, Australia
    Mol Imaging Biol 7:236-43. 2005
    ..Identification of a PPS and/or change in management was documented in 38% of cases, the majority of which were lung or pancreatic cancer. These findings are worthy of evaluation in a prospective study...
  40. ncbi Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Lung Cancer 49:95-108. 2005
    ..PET-response, survival and patterns of failure data are presented with long-term follow-up...
  41. ncbi Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?
    Michael G Poulsen
    University of Queensland, Southern Zone Radiation Oncology, Raymond Tce, South Brisbane, QLD, Australia
    Int J Radiat Oncol Biol Phys 64:114-9. 2006
    ....
  42. ncbi Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Locked Bag No 1, A Beckett St, Melbourne 8006, Australia
    Eur J Nucl Med Mol Imaging 32:1384-91. 2005
    ..The purpose of the study was to evaluate [(18)F]fluoromisonidazole (FMISO) PET in advanced head and neck cancer during hypoxia-targeting therapy...
  43. ncbi The 'QUAD SHOT'--a phase II study of palliative radiotherapy for incurable head and neck cancer
    June Corry
    Division of Radiation Oncology, Peter MacCullum Cancer Centre, East Melbourne, Victoria, Australia
    Radiother Oncol 77:137-42. 2005
    ..Secondary objectives were to prospectively evaluate toxicity, quality of life (QoL) and survival in these patients...
  44. ncbi Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncolog
    Danny Rischin
    Division of Haematology and Medical Oncology, Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
    J Clin Oncol 24:2098-104. 2006
    ....
  45. ncbi The role of PET-CT in the management of patients with advanced cancer of the head and neck
    June Corry
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag No 1, A Beckett Street, Melbourne 8006, Australia
    Curr Oncol Rep 10:149-55. 2008
    ..We also demonstrate why PET-CT should be an integral part of modern management of head and neck cancer...
  46. ncbi How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?
    Guohui Wang
    Department of Nuclear Medicine, Cancer Center, Sun Yat Sen University, Guangdong, PR China
    Cancer 109:117-24. 2007
    ..The aim of the study was to evaluate how oncologists deal with focal extrathyroidal FDG abnormalities considered by imaging specialists to be unrelated to the referral indication...
  47. ncbi Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma
    Caroline A Connell
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia
    Head Neck 29:986-95. 2007
    ..The aim of this study was to determine prospectively the incremental value of positron emission tomography/computed tomography (PET/CT) over conventional assessment (clinical examination and CT/MRI imaging)...
  48. ncbi Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins
    Danny Rischin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 69:S61-3. 2007
  49. ncbi Relapse patterns in WHO 2/3 nasopharyngeal cancer: is there a difference between ethnic Asian vs. non-Asian patients?
    June Corry
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia
    Int J Radiat Oncol Biol Phys 64:63-71. 2006
    ....
  50. ncbi High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07
    Michael Poulsen
    Mater Queensland Radium Institute, Raymond Tee, South Brisbane, QLD 4101 Australia
    J Clin Oncol 21:4371-6. 2003
    ..The effectiveness of synchronous carboplatin, etoposide, and radiation therapy was prospectively assessed in a group of patients with high-risk Merkel cell carcinoma (MCC) of the skin...
  51. ncbi FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burden
    Michael R MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Acta Oncol 42:48-54. 2003
    ..027) but not pre-PET stage, weight loss or metastasis site correlated with survival. PET-detected metastatic tumor burden appeared to influence survival and should be evaluated as a prognostic factor in NSCLC...
  52. ncbi Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    J Clin Oncol 21:1285-92. 2003
    ..PET is known to provide a more accurate estimate of true extent of disease than CT when used to stage non-small-cell lung cancer (NSCLC)...
  53. ncbi The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor
    Gerald B Fogarty
    Division of Radiation Oncology, Peter MacCallum Cancer Institute, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Head Neck 25:138-45. 2003
    ..To assess the role of PET in this scenario in our institution, an audit was performed...
  54. ncbi Phase II trial of continuous infusion carboplatin, 5-fluorouracil, and radiotherapy for localized cancer of the esophagus
    Michael Jefford
    Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Am J Clin Oncol 25:277-82. 2002
    ..This combination has resulted in response data comparable to that of larger studies of cisplatin-containing regimens and warrants further study, ideally in a phase III randomized controlled trial...
  55. ncbi Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation
    Rodney J Hicks
    Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 60:412-8. 2004
    ..Prognostic stratification provided by PET is not compromised by inflammatory changes if a meticulous visual response assessment technique is used...
  56. ncbi Intensity-modulated radiotherapy: examples of its utility in head and neck cancer
    Sandro Porceddu
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Australas Radiol 48:51-7. 2004
    ..It is, therefore, desirable for several clinical applications and essential in some, if unacceptable compromises are not to be made...
  57. ncbi Paranasal sinus tumors: Peter MacCallum Cancer Institute experience
    Sandro Porceddu
    Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Head Neck 26:322-30. 2004
    ....
  58. ncbi Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience
    Robert Blum
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, East Melbourne, Vic, Australia
    Am J Clin Oncol 27:164-71. 2004
    ..PET-CR conferred longer median time to progression (13.7 months) than no CR (9.7 months). FDG-PET for SCLC was often discordant with conventional assessment and frequently influenced management...
  59. ncbi Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma
    Danny Rischin
    Division of Haematology and Medical Oncology, and Statistical Centre, Peter MacCallum Cancer Centre, Melbourne, Australia
    Head Neck 26:435-41. 2004
    ..Sinonasal undifferentiated carcinoma (SNUC) is an uncommon malignancy associated with poor prognosis. The optimal treatment approach for SNUC has not been established was performed...
  60. ncbi 'Boomerang' technique: an improved method for conformal treatment of locally advanced nasopharyngeal cancer
    June Corry
    Division of Radiation Oncology, Peter MacCallum Cancer Institute, St Andrews Place, Melbourne, Victoria, Australia
    Australas Radiol 48:170-80. 2004
    ..A derivative of the Boomerang technique, excluding the parallel opposed component, is now our standard for patients with locally advanced nasopharyngeal cancer when IMRT is not available...
  61. ncbi Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma
    Sandro V Porceddu
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, VC, Australia
    Int J Radiat Oncol Biol Phys 60:365-73. 2004
    ..To describe the use of postoperative concurrent chemoradiotherapy, with either weekly cisplatin or carboplatin, for high-risk head-and-neck squamous cell carcinoma (HNSCC) in a single institutional setting...
  62. ncbi Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck
    Robert E Ware
    The Department of Diagnostic Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Head Neck 26:1008-17. 2004
    ..CONCLUSION: PET added significantly to the value of CE in restaging disease in patients with structural abnormalities after definitive treatment of HNSCC. Management decisions based on PET were appropriate in most patients...
  63. ncbi Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]
    Masahiro Fukuoka
    Fourth Department of Internal Medicine, Kinki University School of Medicine, 377 2 Ohnohigashi Osakasayama, Osaka 589, Japan
    J Clin Oncol 21:2237-46. 2003
    ....
  64. ncbi The local-regionally advanced nasopharyngeal carcinoma jigsaw puzzle: where does the chemotherapy piece fit?
    Danny Rischin
    J Clin Oncol 20:1968-70. 2002
  65. ncbi Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma
    Sarah Jane Dawson
    Department of Haematology and Medical Oncology, The University of Melbourne, Melbourne, Victoria, Australia
    Anticancer Drugs 19:547-52. 2008
    ..Sunitinib seems to be a promising agent in the treatment of thyroid cancers and this requires validation in future clinical trials...
  66. ncbi Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition
    Joan Albanell
    Oncology Service, Vall d'Hebron University Hospital, Paseo Vall d'Hebron 119-129, Barcelona 08035, Spain
    J Clin Oncol 20:110-24. 2002
    ....
  67. ncbi Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Clin Cancer Res 9:2040-8. 2003
    ..They appeared to be a sensitive tool to monitor clinical changes for the five tumor types in these trials and showed that ZD1839 has the potential to improve patients' QoL...
  68. ncbi Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma
    Sarah Jane Dawson
    Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Nat Clin Pract Oncol 3:104-7. 2006
    ..Seven months later he presented with a 4-day history of fatigue, muscle cramps, ataxia, paraesthesia, and blurred vision...
  69. ncbi Merkel cell carcinoma--current therapeutic options
    Michael Poulsen
    Mater Queensland Radium Institute, Raymond Terrace, South Brisbane, Queensland 4101, Australia
    Expert Opin Pharmacother 4:2187-92. 2003
    ..The presence of distant disease carries a grave outlook with responses to chemotherapy occurring frequently, albeit of short duration...
  70. ncbi Strategies to overcome accelerated repopulation and hypoxia--what have we learned from clinical trials?
    June Corry
    Head and Neck Radiation Oncology Unit, Division of Radiation Oncology, University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia
    Semin Oncol 31:802-8. 2004
    ....
  71. ncbi A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer
    Danny Rischin
    Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia
    Gynecol Oncol 93:417-21. 2004
    ..To determine the activity of capecitabine in women with platinum-resistant ovarian cancer...
  72. ncbi A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy
    Sherene Loi
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Chemother Pharmacol 54:407-14. 2004
    ..CONCLUSION: CrEL at this dose and schedule does not appear to be a major contributory factor to the platelet-sparing effect of paclitaxel when combined with carboplatin, nor does it alter the pharmacokinetics of carboplatin...
  73. ncbi Phase II study of imatinib in patients with small cell lung cancer
    Bruce E Johnson
    Dana Farber Cancer Institute, Brigham and Women s Hospital and Massachusetts General Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:5880-7. 2003
    ..The purpose of our study was to assess the objective response to imatinib administered to patients with small cell lung cancer (SCLC)...
  74. ncbi An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin
    Richard W Tothill
    Ian Potter Centre for Cancer Genomics and Predictive Medicine, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St. Andrew's Place, East Melbourne, Victoria, Australia
    Cancer Res 65:4031-40. 2005
    ..We show that the microarray SVM classifier was capable of making high confidence predictions in 11 of 13 cases. These predictions were supported by comprehensive review of the patients' clinical histories...